News | November 05, 2010

Final Patient Enrolled for PAD Study

November 5, 2010 – The final patient has been enrolled in a trial studying a balloon-expandable covered stent for those with occlusive disease of the iliac artery. The iCARUS trial is investigating the iCast stent, made by Atrium Medical.

Iliac artery occlusive disease is one form of peripheral arterial disease (PAD). Patients with PAD typically have intermittent upper and lower leg pain, commonly known as “claudication” or “rest pain.” Lower extremity leg pain is often caused by decreased blood flow due to a narrowing or thrombotic occlusion of peripheral blood vessels. It can also be a result of atherosclerosis along the luminal walls of leg arteries, including the common iliac, external iliac, femoral and popliteal vessels.

In the study, the stent is used to re-open diseased iliac arteries, which feed blood flow to the legs from the aorta.

“I am thrilled that we have completed enrollment in the iCARUS trial,” said John R. Laird, M.D., U.C. Davis vascular center in Sacramento, Calif., and principal investigator of the study. “This is an important study that will help define the role of the iCast covered stent for the treatment of iliac occlusive disease.”

The iCast balloon-expandable covered stent is a micro-thin biomaterial film encapsulating a stainless steel slotted tube stent. Since it is pre-mounted by the company onto a balloon delivery catheter, it offers single-operator deployment through a very small diameter introducer sheath, without the need for surgery. The delivery system is compatible with 0.035-inch guidewires.

The stent is currently an investigational device in the United States and is currently FDA-approved for treating tracheobronchial strictures.

For more information: www.atriummed.com.


Related Content

News | Cardiovascular Clinical Studies

May 6, 2026 — Image Analysis Group (IAG), a global imaging CRO headquartered in London, U.K., and HeartcoR Solutions ...

Home May 06, 2026
Home
News | Cardiovascular Clinical Studies

April 9, 2026 — Mount Sinai researchers have created an analytic tool using machine learning that can predict ...

Home April 14, 2026
Home
News | Cardiovascular Clinical Studies

April 13, 2026 —The American Heart Association (AHA) has granted Case Western Reserve University the Rapid Impact ...

Home April 13, 2026
Home
News | Cardiovascular Clinical Studies

April 2, 2026 — Iterative Health and US Heart & Vascular (USHV) have announced a strategic partnership to advance ...

Home April 02, 2026
Home
News | Cardiovascular Clinical Studies

March 4, 2026 — UltraSight, a provider of AI-guided cardiac imaging workflows, has announced Late-Breaking clinical ...

Home March 04, 2026
Home
News | Cardiovascular Clinical Studies

Feb. 9, 2026 — HTA and MedAxiom have opened applications for the 2026 HeartX program, a cardiovascular-focused ...

Home February 18, 2026
Home
News | Cardiovascular Clinical Studies

Jan. 5, 2026 — Medera Inc., a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by ...

Home January 05, 2026
Home
News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
Subscribe Now